Introduction
The human tumor suppressor gene DAL-1/4.1B (differentially expressed in adenocarcinoma of the lung) was identified using Differential Display PCR (DDPCR) as a gene whose expression was lacking in primary nonsmall-cell lung cancer (NSCLC) when compared with matched normal tissue (Tran et al., 1999) . This gene product was determined to be a new member of the Protein 4.1 superfamily by virtue of the presence of a 336 amino-acid N-terminal region sharing significant identity to the FERM (4.1/Ezrin/Radixin/Moesin) domain present in all 4.1 family proteins (Chishti et al., 1998) . Members of this family, which include the neurofibromatosis 2 tumor suppressor protein merlin or schwannomin (Rouleau et al., 1993; Trofatter et al., 1993) , are proteins that localize to the cytoplasmic side of the plasma membrane and link membrane proteins with the spectrin/actin cytoskeleton (Tsukita et al., 1994) . Like merlin and now 4.1R, which have been shown to suppress growth in schwannoma and meningioma cell lines Robb et al., 2004) , DAL-1/4.1B negatively regulates cell growth in several different cell types. For example, when introduced into DAL-1/4.1B-null lung and breast cancer cells, this new Protein 4.1 family member significantly suppresses growth (Tran et al., 1999; Charboneau et al., 2002) . Similar results are obtained when DAL-1/4.1B is overexpressed in meningioma cell lines ) and the glioma cell line U87 (Newsham, data not shown).
DAL-1/4.1B maps to a region on human chromosome 18p11.3 that undergoes frequent loss of heterozygosity (LOH) in a significant proportion of lung, breast and brain tumors (Tran et al., 1998) . Extensive analysis on patients presenting with multiple stages of breast cancer revealed that 18p11.3 allelic deletions occur in greater than 55% of ductal carcinoma in situ (DCIS) tumors (Kittiniyom et al., 2001) , suggesting that events disrupting DAL-1/4.1B expression occur early in the progression of this disease although intragenic mutations are uncommon (Kittiniyom et al., 2004) . Furthermore, significant LOH and concomitant loss of DAL-1/4.1B protein has also been reported in greater than 70% of sporadic meningiomas . Interestingly, combined loss of DAL-1/4.1B and merlin is common , suggesting that both proteins contribute to a tumorigenic phenotype, at least in these central nervous system tumors, despite being structurally related members.
The mechanism(s) by which DAL-1/4.1B suppresses tumor cell growth is not clearly understood. Preliminary studies in MCF-7 breast cancer cells show that DAL-1/ 4.1B increases cell attachment while inducing apoptosis (Charboneau et al., 2002) . Other studies performed on rat schwannoma cell lines suggest that DAL-1/4.1B inhibits cell motility and adhesion . Defining the interactions of DAL-1/4.1B with other proteins in different tumor types might elucidate the pathway(s) in which this tumor suppressor protein participates. An important domain for protein interactions in 4.1 family members is the shared N-terminal localization domain or FERM domain (Chishti et al., 1998) . Previous studies of merlin and ERM (Ezrin/ Radixin/Moesin) proteins have revealed binding of this N-terminal domain to a charged amino-acid motif in the cytoplasmic tail of transmembrane proteins CD44, CD43 and intracellular adhesion molecule 1 (ICAM1) (Legg and Isacke 1998; Yonemura et al., 1998) . Contact inhibition of cell growth in rat schwannoma cells is mediated by merlin's regulated interaction with CD44 (Morrison et al., 2001 ). Characterizing such FERMmediated protein-protein interactions will be important for understanding the function of DAL-1/4.1B.
To determine how DAL-1/4.1B functions to suppress the growth of human tumor cells, yeast two-hybrid interaction cloning was performed on a human lung cDNA library using the 336 amino-acid FERM domain of DAL-1/4.1B as bait. Screening of over 2 million colonies identified several interacting proteins, one of which represented 45% of the isolated cDNA clones. This protein, protein arginine N-methyltransferase 3 (PRMT3) is a member of an expanding family of enzymes that catalyse the sequential transfer of methyl groups from S-adenosyl-L-methionine to the guanidino nitrogens of arginine residues in proteins (Aletta et al., 1998; Gary and Clarke, 1998; Tang et al., 1998) . Sequence comparisons indicate that all mammalian PRMT family members contain a common catalytic domain, but variable N-and C-terminal regions . Protein methylation by PRMT enzymes has been shown to regulate transduction of signals to the nucleus, transcription regulation through nuclear receptors, and RNA transport between the nucleus and cytoplasm (McBride and Silver, 2001) . In this study, an association of PRMT3 with the tumor suppressor protein DAL-1/4.1B was confirmed by coimmunoprecipitation and in vitro binding assays. DAL-1/4.1B interaction is not exclusive within the arginine methyltransferase family although only one other Protein 4.1 family member tested, 4.1G, was found to complex with PRMT3. DAL-1/4.1B protein is not itself an in vitro substrate for PRMT3, but its interaction with this methyltransferase does inhibit the methylation of 'RGG' consensus sequences in vitro and cellular substrates in vivo. These results suggest that the interaction between a tumor suppressor and a posttranslational methylation enzyme might be biologically important in controlling tumorigenesis.
Results

Tumor suppressor DAL-1/4.1B interacts with PRMT3
Yeast two-hybrid interaction cloning was performed to isolate potential binding partners of protein DAL-1/ 4.1B, originally identified as a tumor suppressor in lung tumor cells. A lung cDNA library was screened using a bait construct encoding the FERM domain (residues 1-337) of DAL-1/4.1B (Figure 1a) . Analysis of more than 2 million cotransfectants led to the isolation of 20 positive colonies after two rounds of screening. Sequence analysis revealed that nine of these colonies contained cDNAs encoding human protein PRMT3. cDNA-insert sizes for PRMT3 ranged between 1.5 and 2.0 kb. In 1998, Tang et al. (1998) reported the aminoacid sequence for human PRMT3, lacking approximately 10 amino acids at the N-terminus. Sequence analyses indicated that only cDNAs encoding parts of the C-terminal region, which encodes the catalytic-core domain of the protein, were present in these positive clones, suggesting that this region is sufficient for interaction with DAL-1/4.1B (Figure 1a ). To investigate protein expression profiles for human PRMT3, a polyclonal anti-PRMT3 antibody, raised against rat PRMT3 amino acids 166-528 (Tang et al., 1998) , was used to screen several human tumor cell lines (Figure 1b) . The lung cancer cell line NCI-H460, breast cancer lines MCF-7 and T47D and kidney cell line 293GP show expression of the 68 kDa band corresponding to the expected size of human PRMT3 when compared with the protein band found in rat heart homogenate. Based on equivalent loading of protein (confirmed by Coomassie staining), 293GP cells express high levels of the approximately 68 kDa PRMT3 protein, whereas the brain tumor cell line U87 expresses minimally detectable amounts of PRMT3 protein.
Additional bands at 95 and 60 kDa may represent antibody crossreactivity with other related protein species sharing homology to PRMT3 and/or PRMT3 variants produced by alternate splicing. Lysates were also analysed for the presence of endogenous DAL-1/ 4.1B (Figure 1b) . NCI-H460, T47D and 293GP cells expressed DAL-1/4.1B, while MCF-7 and U87 cell lines did not. Growth of both MCF-7 (Charboneau et al., 2002) and U87 cells (Newsham, unpublished data) have DAL-1/4.1B inhibits PRMT3 methyltransferase activity V Singh et al been shown to be suppressed upon re-expression of the DAL-1/4.1B protein.
To confirm the interaction of DAL-1/4.1B and PRMT3 in mammalian cells, expression vectors containing the original 2A3 cDNA clone for DAL-1/4.1B (pcDNA3-DAL-1/4.1B) and Xpress epitope-tagged PRMT3 (pcDNA4-PRMT3) were transiently transfected into 293GP cells. These cells were chosen for their high transfection efficiency. An epitope-tagged PRMT3 construct was used as preliminary studies indicated that the rat PRMT3 polyclonal antibody was inadequate at immunoprecipitating human PRMT3. The 2A3 DAL-1/4.1B cDNA produces an 80 kDa variant of the 110 kDa endogenous protein, which possesses all sequences required for growth suppression in tumor cell lines . Western analysis of immunoprecipitates generated with both DAL-1/4.1B-specific and PRMT3 epitope-tag Xpress antibodies revealed that human PRMT3 coimmunoprecipitates with DAL-1/4.1B (Figure 2a ). The interaction of PRMT3 and DAL-1/4.1B was also assessed in human cell lines expressing both endogenous DAL-1/4.1B and PRMT3. Immunoprecipitation of DAL-1/4.1B in the NCI-H460 and T47D cell lines, followed by Western analysis with the polyclonal anti-PRMT3 or anti-DAL-1/4.1B antibodies show that endogenous PRMT3 associates with endogenous DAL-1/4.1B (Figure 2b In vitro binding assays were also performed to further confirm this interaction. Radiolabeled DAL-1/4.1B or PRMT3 proteins were incubated with either glutathione-S-transferase (GST)-PRMT3 or GST-DAL-1/ 4.1B, respectively, and protein complexes were retrieved on GST affinity beads. Following centrifugation, the presence of bound radiolabeled protein was analysed by SDS-PAGE separation and autoradiography. As shown in Figure 3 , fractions of bound [
3 H]DAL-1/4.1B and [ 3 H]PRMT3 proteins were significantly higher than in the supernatant when confronted with the opposing GST-fusion protein. As a negative control, an in vitro binding assay was performed using [
3 H]14-3-3b and GST-PRMT3. Protein 14-3-3 molecules are abundantly expressed proteins that have been shown to have affinity for a wide variety of cellular proteins (Fu et al., 2000) . Protein 14-3-3b did not interact with PRMT3. Binding assays were also performed with a zinc-finger domain fragment (GST-ZF) and a catalytic domain fragment (GST-PRMT3DZF) of PRMT3 (see Figure 1a ). The Cterminal end of PRMT3 (encompassed in GST-PRMTDZF; amino acids 184-528) interacted with DAL-1/4.1B (Figure 3b ), supporting the original yeast two-hybrid results that identified cDNAs containing the C-terminal end of the PRMT3 coding region. The Nterminal zinc-finger domain of PRMT3 (GST-ZF; amino acids 1-183) showed no affinity for DAL-1/ 4.1B. Thus, DAL-1/4.1B interacts with PRMT3 both in vivo and in vitro via the catalytic C-terminal core region of the protein.
PRMT and Protein 4.1. family interactions
Previous work by our group has shown that NF2/merlin and DAL-1/4.1B are structurally similar and function to suppress growth in meningiomas . In addition, NF2/merlin and DAL-1/4.1B have been shown to share a portion of the spectrum of binding partners . Therefore, the ability of PRMT3 to interact with other members of the Protein 4.1 family was examined. Radiolabeled N-terminal FERM domain-containing regions of NF2/merlin, ezrin and radixin as well as full-length 4.1B-like subfamily members 4.1G and 4.1R80 were confronted with GST or GST-PRMT3 proteins and assayed for their ability to interact in vitro. Results of these binding assays are shown in Figure 4 . Protein 4.1 family member 4.1G was the only other Protein 4.1 family member other than DAL-1/4.1B to show an affinity for interacting with PRMT3.
Given that the catalytic core domain of PRMT3 is the region of interaction with DAL-1/4.1B and that the core domains of the PRMT family members are highly conserved, we also determined whether the DAL-1/4.1B interaction was mutually exclusive to PRMT3. PRMT proteins 1-6 were examined for their ability to interact by both in vitro binding assays and coimmunoprecipitation reactions in 293GP cells ( Figure 5 ). PRMT 3, 5 and Figure 3 DAL-1/4.1B interacts directly with PRMT3. GST-fusion products (2 mg each) of DAL-1/4.1B, PRMT3, PRMT3DZF and ZF were generated and confronted in vitro with 5 ml of TnTradiolabeled proteins DAL-1/4.1B, PRMT3 and 14-3-3b in various combinations. Aliquots of each radiolabeled protein were run as a reference. Equivalent amounts of protein collected on GST-beads and remaining in the supernatant were analysed by electrophoresis and autoradiography. (a) Both GST-PRMT3 and GST-DAL-1/ 4.1B directly interact with their respective radiolabeled protein partners. This interaction is specific for DAL-1/4.1B and PRMT3, as PRMT3 was not able to bind the ubiquitously expressed cytoplasmic-binding protein 14-3-3b. (b) Radiolabeled DAL-1/ 4.1B was confronted with either the N-terminal zinc-finger (GST-ZF) or catalytic domain of PRMT3 (GST-PRMT3DZF). DAL-1/ 4.1B interacted directly with the catalytic domain but not with the zinc-finger domain. TnT rxn: transcription and translation reaction protein Figure 4 Protein 4.1 family binding to PRMT3. Protein 4.1 family members DAL-1/4.1B, 4.1G, 4.1R80 as well as the FERM domains of NF2/merlin, ezrin and radixin were examined for their ability to bind to PRMT3 in vitro. Each TnT-radiolabled 4.1 family protein was incubated with equimolar amounts of either GST-PRMT3 or GST control proteins. GST-protein complexes were purified on glutathione Sepharose beads and separated by SDS-PAGE electrophoresis as described in the Materials and methods. In addition to DAL-1/4.1B, protein 4.1G was the only other 4.1 family member tested that showed an affinity for binding to PRMT3 DAL-1/4.1B inhibits PRMT3 methyltransferase activity V Singh et al 6 were found to complex with DAL-1/4.1B in both assays, whereas PRMT 1 and 2 bound in vitro but not when coexpressed in 293GP cells. It is possible that a cellular substrate exists which regulates the interaction of DAL-1/4.1B with these particular PRMTs. PRMT4 did not appear to interact with DAL-1/4.1B in either assay suggesting that it is not a binding partner for this tumor suppressor protein, although the apparent high background binding to GST may be masking such an interaction.
DAL-1/4.1B inhibits PRMT3 activity in vitro PRMT3 is a type I arginine methyltransferase responsible for methylating the terminal guanidino nitrogens of arginine residues to produce mono-and asymmetric dimethylarginine in proteins (Aletta et al., 1998; Tang et al., 1998) . In vitro assays measuring the potential methylation of DAL-1/4.1B by PRMT3 were performed using GST fusion proteins and the in vitro methylaccepting substrate glycine-and arginine-rich (GAR). GAR contains 14 arginine residues within a glycine-rich region, the majority of which reside within 'RGG' consensus methylation sites, and has been shown previously to be a PRMT3 methylation substrate (Lischwe et al., 1985; Tang et al., 1998) . Incubation of GST-PRMT3 in the presence of GAR and [ 3 H]AdoMet results in the generation of a diffusely radiolabeled band at 30-35 kDa, which represents partially proteolized, methylated fragments of GST-GAR (Figure 6b ). When GST-PRMT3 and GST-DAL-1/4.1B proteins were combined, no methylation of the DAL-1/4.1B protein was observed, indicating that DAL-1/4.1B is not itself a substrate for PRMT3. Such methylation products would be expected to migrate around 97 kDa (Figure 6a) . The 3 H-labeled product migrating at 28 kDa was shown to represent a bacterial methyl-acceptor, which copurified with DAL-1/4.1B during the preparation of the GST-DAL-1/4.1B fusion protein was cleared when more stringent washing conditions were applied during protein purification (data not shown). This 28 kDa species is not observed in the lane with the GST-PRMT3 protein alone.
Although the DAL-1/4.1B protein is not methylated by PRMT3, the PRMT3/DAL-1/4.1B-complex might Figure 5 Binding of DAL-1/4.1B to members of the PRMT family. The interaction of DAL-1/4.1B and other members of the PRMT family was investigated using both in vitro confrontation assays and coimmunoprecipation experiments in 293GP cells. (a) Equimolar amounts of GST and GST-DAL-1/4.1B were incubated with 5 ml of TnT radiolabeled PRMT 1, 2, 3, 4, 5 and 6 proteins as described in the Materials and methods. GST complexes were purified by affinity chromatography and the proteins fractionated by SDS gels. The region of the gel where PRMT proteins migrated is displayed. A 2-5 ml aliquot of each TnT-radiolabeled protein was run as a control. These assays show that PRMT4 is the only family member which does not show affinity for binding to DAL-1/4.1B in vitro. (b) Individual PRMT proteins and DAL-1/4.1B were coexpressed in 293GP cells and the complexes were immunoprecipitated using the rabbit polyclonal anti-DAL-1 antibody 3A-1. Complexes were centrifuged, fractionated by SDS gel electrophoresis and analysed by Western blot analysis. PRMT proteins were visualized using PRMT-specific antibodies for PRMT 1, 3 and 5, while PRMT 2, 4 and 6 were identified via their 5 0 Xpress epitope tag. A fraction of the total cell lysate (TCL) was used to confirm expression levels and PRMT protein sizes. PRMT 3, 5 and 6 were found to coimmunoprecipitate in these experiments, while PRMT 1, 2 and 4 did not form complexes in these cells. The apparent binding of PRMT 1 and 2 with DAL-1/4.1B in vitro (Figure 4 ) but lack of interaction in 293GP cells suggests there may be additional cellular proteins which may cooperate to regulate these interactions in vivo. IgG, immunoglobulin heavy chain 
DAL-1/4.1B expression inhibits PRMT3 methylation in vivo in MCF-7 cells
If the overexpression of DAL-1/4.1B results in the hypomethylation of PRMT3 cellular substrates in vivo, then protein extracts from DAL-1/4.1B-expressing cells should be good methyl acceptors for in vitro methylation reactions using the GST-PRMT3 enzyme. To assess this, we used a breast cancer cell line, MCF-7 cl27, which has been engineered to be inducible for expression of the DAL-1/4.1B protein (Charboneau et al., 2002) . MCF-7 cl27 cells were induced to express DAL-1/4.1B protein for 48 h. Cell lysates were collected and in vitro methylation reactions were performed in the presence of GST or GST-PRMT3 proteins (Figure 8) . In uninduced cl27 cell lysates, GST-PRMT3 did not catalyse the labeling of proteins in the presence of [ 3 H]AdoMet indicating that the endogenous PRMT3 activity in MCF-7 cells had successfully methylated its cellular substrates in vivo. However, in cells grown in the presence of induced DAL-1/4.1B protein, addition of GST-PRMT3 to the cell lysate catalysed significant in vitro methylation of a variety of cellular proteins as shown by the ladder of labeled bands in lane 2 of Figure 8 . Such in vitro methylation indicates that the induced DAL-1/4.1B protein inhibited the ability of endogenous PRMT3 to methylate cellular substrates, consistent with our in vitro methylation assay results shown in Figure 7 . No methylation was found in either cell lysate when only GST control protein was added.
To confirm that the GST-PRMT3 protein used in these assays was active, the in vitro substrate GST-GAR was added to the methylation reaction. This produced the expected radiolabeled band at 30-35 kDa (Figure 8 , middle panel) representing the methylated fragments of GST-GAR previously shown in Figures 6 and 7 . Furthermore, we hypothesized that if additional GST-DAL-1/4.1B protein was added to reactions using lysates from DAL-1/4.1B-expressing cells, this additional protein should serve to quench the GST-PRMT3-mediated in vitro methylation of cellular substrates. This was indeed the case where the ladder of labeled proteins produced is significantly diminished (Figure 8 , right 4) . Middle panel, the active nature of the purified GST-PRMT3 protein was confirmed by the addition of 2 mg of the in vitro methylation substrate GST-GAR (lane 5). Right panel, the addition of purified GST-DAL-1/ 4.1B protein (7.5 mg) to the in vitro methylation assay following endogenous expression of DAL-1/4.1B protein significantly inhibits the ability of GST-PRMT3 protein to methylate hypomethylated cellular substrates (compare lanes 6 and 7), further supporting a role for DAL-1/4.1B in the inhibition of PRMT3. Additionally, the presence of GST-DAL-1/4.1B does not stimulate in vitro methylation directly in the uninduced or DAL-1/4.1B-induced cell extracts. kD, kilodaltons; GST, glutathione-S-transferase DAL-1/4.1B inhibits PRMT3 methyltransferase activity V Singh et al panel) from that shown without additional GST-DAL-1/4.1B (Figure 8, left panel) . Additionally, the lack of methylation seen in lane 6 shows that GST-DAL-1/4.1B does not stimulate methylation in vitro, further supporting the ability of endogenous PRMT3 to methylate substrates in vivo (lane 1) in the absence of induced DAL-1/4.1B protein expression.
Discussion
The tumor suppressor DAL-1/4.1B shares significant sequence similarity in its N-terminal FERM domain with members of the Protein 4.1 superfamily that includes the NF2 tumor suppressor merlin. Like other 4.1 family member proteins, DAL-1/4.1B has been localized to regions of the plasma membrane at points of cell-to-cell contact by immunocytochemistry (Tran et al., 1999) . While merlin has been shown to interact with several proteins including NHERF, SCHIP and CD44 (Murthy et al., 1998; Yonemura et al., 1998; Goutebroze et al., 2000) , comparatively less is known about DAL-1/4.1B-binding partners. To determine the protein interactions that might transduce the DAL-1/ 4.1B growth suppressor signal, yeast two-hybrid analysis of a lung cDNA library was performed using the FERM domain of DAL-1/4.1B as bait. We identified the human protein PRMT3 gene (Tang et al., 1998) as a binding partner of DAL-1/4.1B. This interaction was also seen in mammalian cells by coimmunoprecipitation, and supported by in vitro confrontation experiments. Despite significant homology in the N-terminal FERM domain within the Protein 4.1 superfamily, the domain responsible for interaction of DAL-1/4.1B and PRMT3, Protein 4.1G was the only other family member tested that was also found to complex with PRMT3 ( Figure 4 ). PRMT3 protein has been immunolocalized to the cytoplasm in rat cells (Tang et al., 1998) and as a cytoplasmic GFP fusion protein in human HeLa cells (Frankel et al., 2002) . Expression analysis in a variety of tissues demonstrates almost universal expression for this methyltransferase (Tang et al., 1998) . The fact that DAL-1/4.1B and PRMT3 are expressed in the same tissues and associate in vitro and in vivo suggests biological relevance for a DAL-1/4.1B and PRMT3 complex. Despite their interaction, DAL-1/4.1B was determined not to be a methyl-accepting substrate for PRMT3 as assayed by in vitro methylation (Figure 6 ) but rather appears to inhibit PRMT3-mediated methylation activity in vitro and in vivo (Figures 7 and 8) .
Currently, the mammalian protein methyltransferase family consists of seven gene products Frankel et al., 2002; Miranda et al., 2004) . These enzymes mediate methylation, typically although not exclusively within RGG consensus sequences, in the context of GAR regions through the transfer of methyl groups from the donor S-adenosyl-L-methionine (AdoMet) (Lischwe et al., 1985; Tang et al., 1998) . All PRMT proteins share a relatively conserved catalytic core domain -the domain through which PRMT3 was shown to interact with DAL-1.4B (Figure 3) . A complex binding pattern for the PRMT family and DAL-1/4.1B was determined where PRMT 3, PRMT 5 and PRMT 6 were found to interact both in vitro and in vivo, while PRMT 1 and PRMT 2 bound in vitro but did not coimmunoprecipitate from 293GP cells. PRMT4 did not interact with DAL-1/4.1B in either assay.
The biological interaction of DAL-1/4.1B and PRMT proteins may be additionally regulated by the widely varying length and sequence of the N-and C-terminal ends of these family members or by the presence of other binding partners. In the case of PRMT3, a 194 amino acid N-terminal portion contains two motifs -a zincfinger domain (Cys 48 -His
69
) and a tyrosine phosphorylation consensus sequence (Tyr 85 -Phe 93 ) (Tang et al., 1998) . This phosphorylation sequence (GLEFYGYIK) is similar to the JAK kinase substrate site GPKGYIK present in STAT1 (Shuai et al., 1992) , an identified substrate of PRMT1 (Mowen et al., 2001 ). PRMT2, whose activity has not yet been demonstrated, contains an SH3-binding domain in its N-terminal portion (Aletta et al., 1998) . The presence or absence of Nterminal-interacting or regulatory domains may be important for defining the specificity of these proteinmethylating enzymes.
If arginine methylation is an irreversible modification, as is generally believed, then regulation of protein methylation would presumably have to occur at the level of modulating either the activity or the level of expression of the methyltransferase enzyme itself. The possibility that interacting proteins critically modulate PRMT3 kinetics and specificity is worth considering. Support for this hypothesis comes from previous studies on PRMT1. Yeast two-hybrid analysis with the immediate early gene TIS21/BTG1 revealed a strong interaction with the catalytic domain of PRMT1. TIS21 was found not to be a substrate for PRMT1 methylation, but its binding enhanced the ability of PRMT1 to methylate substrates in hypomethylated RAT1 extracts (Lin et al., 1996) . Another family member, BTG2, is a candidate tumor suppressor regulating the G1/S transition of the cell cycle. It too has been shown to interact with PRMT1 and enhance methylation of histone H2A (Berthet et al., 2002) .
This current study shows an alternate situation in which DAL-1/4.1B appears to inhibit the level of posttranslational modification of arginine residues by PRMT3 as measured by decreased methylation of a GST-GAR substrate in vitro (Figure 7 ) and more importantly, as detected in cells grown in the presence of endogenously induced DAL-1/4.1B protein (Figure 8) . Interestingly, little PRMT3 methylation was detected in RAT1 cell extract assays unless the protein lysate had been pretreated with RNase (Frankel and Clarke, 1999) , suggesting methylation substrates might exist in complexes with RNA species that may also inhibit methyltransferase action. Binding of DAL-1/4.1B may inhibit the release of such inhibitors from methylation substrates (indirect inhibition) and this may involve the zinc-finger domain of PRMT3 or it may structurally prevent the interaction of these protein substrates with DAL-1/4.1B inhibits PRMT3 methyltransferase activity V Singh et al the catalytic domain of PRMT3 (direct inhibition). DAL-1/4.1B has also been shown to complex with several isoforms of the adapter protein 14-3-3 . These proteins stimulate protein-protein interactions as well as regulate the subcellular location of proteins and have been implicated in cell cycle control, signal transduction and apoptosis (reviewed in Muslin and Xing, 2000) . Recent data show that 14-3-3 Z binds both DAL-1/4.1B and 4.1G, the same Protein 4.1 family interaction profile exhibited by PRMT3 (Robb et al., 2004) . In addition, the DAL-1/4.1B FERM sequences required for 14-3-3 (Robb et al., 2004) and PRMT3 (Newsham, unpublished data) protein binding are different, suggesting that DAL-1/4.1B and its ability to regulate PRMT3 could be affected by the simultaneous or alternate presence of a 14-3-3 molecule. In the context of the mammalian cell, therefore, the mechanisms responsible for regulating the binding of such protein and RNA species would be crucial to the functionality of PRMT3.
Many different types of proteins have been identified as targets of arginine methylation by PRMT proteins. The most common targets are RNA-binding proteins, some of which play roles in pre-mRNA processing and nucleocytoplasmic RNA transport. In fact, PRMT3 has recently been shown in the fission yeast Schizosaccharomyces pombe to be a ribosomal protein methyltransferase that affects the cellular level of ribosomal subunits (Bachand and Silver, 2004) . Other general PRMTmethylated proteins include heterogeneous nuclear ribonucleoproteins (hnRNPs) (Kumar et al., 1986; Kim et al., 1997) , poly(A)-binding protein II (Smith et al., 1999) and spliceosomal snRNP proteins SmD1 and SmD3 (Brahms et al., 2000) . Additionally identified targets include fibrillarin (Tang et al., 2000a) , the mitotic Src kinase substrate Sam 68 (Bedford et al., 2000) , Signal Transducer and Activator of Transcription STAT1 (Mowen et al., 2001 ) and interleukin enhancer-binding factor (Tang et al., 2000b) . Recent studies have implicated arginine methylation in modulation of specific intra-and intermolecular interactions of target proteins . For example, methylation in the proline-rich region of Sam 68 , an adaptor protein in signaling pathways, decreases its binding to SH3-containing proteins without affecting binding to WW domain-containing proteins (Bedford et al., 2000) . Although methylation does not affect the overall charge of an arginine residue, it does increase steric hindrance and potentially disrupts hydrogen bonding by removing guanidine hydrogen atoms. Arginine methylation has also been implicated in the regulation of signaling and transcription activation. Methylation of STAT-1 decreases its affinity for the inhibitor PIAS1 and impairs STAT-1's ability to bind DNA (Mowen et al., 2001) . Likewise, methyltransferase interactions with the p160 family of transcriptional coactivators of nuclear hormone receptors also result in an enhancement of gene expression (Chen et al., 1999) . Such expression may also be indirectly affected by alteration of chromatin structure through PRMT methylation of histones (Wang et al., 2001 ).
Protein methylation, therefore, represents an important post-translational modification system that can impact the ability of a variety of proteins to perform their biological functions. The diversity of proteins found to be substrates for PRMT molecules suggests that arginine methylation or protein methylation in general may begin to parallel protein phosphorylation in its complexity. In this report, we show that the tumor suppressor DAL-1/4.1B, which suppresses growth in multiple cell types, interacts with PRMT3 and inhibits its ability to methylate at the archetypal 'RGG' consensus methylation sequences as well as endogenous PRMT3 cellular substrates. How the PRMT3/DAL-1/ 4.1B interaction directly or indirectly relates to DAL-1/ 4.1B growth suppression may partially be explained through the identification of those proteins that are substrates for PRMT3 and whose methylation is altered by the presence of DAL-1/4.1B protein. The identification of these methylation substrates may support the hypothesis that DAL-1/4.1B impacts cell growth through mediating post-translational protein modifications, thereby regulating their ability to function in pathways important in controlling cell growth. This would be a unique mechanism for such tumor suppressor gene function in mammalian cells.
Materials and methods
Yeast two-hybrid analysis to identify proteins that interact with the FERM domain of DAL-1/4.1B Yeast two-hybrid analysis to identify proteins interacting with the FERM domain of DAL-1/4.1B was performed using the ProQuestt Two-Hybrid system (InVitrogen). The FERM domain of DAL-1/4.1B, representing the first 336 amino acids of the DAL-1/4.1B cDNA clone 2A3 (Figure 1a ) (Tran et al., 1999) was amplified using primers 5 0 -ACG-TGT-CGA-CCA TGC-AGT-GCA-AAG-TGA-TAC-3 0 and 5 0 -ACG-TGC-GG C-CGC-CTC-TCC-ATC-CAA-GCT-GCG-3 0 containing SalI and NotI linkers, respectively. The resulting 1015 bp fragment was cloned into the pDBLeu 'bait' vector creating a fusion protein with the GAL-4 transcription factor DNA-binding domain. An adult human lung cDNA library (InVitrogen) encoding expressed cDNAs fused with the GAL-4 transcription factor activation domain was used for screening. More than 2 million cDNA clones were screened with 45 positively interacting colonies being identified based upon growth on leucine-, tryptophan-, uracil-and histidine-lacking plates, as well as the ability to process lacZ substrate. Following secondary screening, 20 colonies were selected. pPC86-cDNA constructs were isolated from the interacting yeast colonies using the Yeast DNA Isolation System (Stratagene) and the inserts were sequenced and analysed with either Thermosequenase Cy 5 or Cy 5.5 terminator sequencing kits (AP Biotech, Inc.) on the Long -Readt System sequencer (Visible Genetics Inc). Homology searches were performed using the Blast algorithm through the National Center for Biotechnology Information (Altschul et al., 1990) .
Cell culture and Western analysis
Lung tumor cell line NCI-H460, and breast carcinoma cell lines T47D and MCF-7 were obtained from the American Type Culture Collection (Manassas,VA, USA). T47D cells DAL-1/4.1B inhibits PRMT3 methyltransferase activity V Singh et al were maintained in RPMI 1640 with 10% fetal calf serum (FCS) and insulin. NCI-H460 cells were maintained in the same medium without insulin. The MCF-7 cl27 cell line is a DAL-1/4.1B-inducible cell line generated from the parental MCF-7 cell line using the Ecdysone muristerone-inducible Expression Kit (InVitrogen) (Charboneau et al., 2002) . This cell line is grown in MEM with 10% FCS, sodium pyruvate, nonessential amino acids and insulin. DAL-1/4.1B expression is induced by the addition of 1-2 mM muristerone to the culture medium for 48 h. Cell lysates were prepared in RIPA buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP40) with protease inhibitors (Boehringer Mannheim). Electrophoresis was performed on either 10 or 12% SDS-PAGE gels (BioRad) and transferred onto PVDF Plus membrane (MSI Inc.) using the BioRad Mini Protean II transfer system as previously described (Tran et al., 1999) .
Coimmunoprecipitation assays
The full-length rat PRMT3 cDNA was cloned in frame into the pcDNA4-Xpress/His vector (InVitrogen), which provides both 5 0 Xpress and His epitope tags. Constructs pcDNA4-PRMT3 and pcDNA3-DAL-1/4.1B (Tran et al., 1999) were cotransfected into 293GP cells using calcium phosphate precipitation. At 2 days after transfection, protein lysates were prepared as described above and immunoprecipitates generated from 1-2 mg of lysate using either the monoclonal antibody against the Xpress epitope tag (InVitrogen) or the polyclonal anti-DAL-1/4.1B antibody 3A-1 (Tran et al., 1999) . Immunoprecipitation was also performed on DAL-1/4.1B and PRMT3 endogenously expressing cell lines NCI-H460 (lung cancer) and T47-D (breast cancer) using the anti-DAL-1/4.1B antibody. Immunoprecipitates were collected on Protein A Agarose beads (Roche Molecular Biochemicals) and washed 3-5 times in RIPA buffer. Protein A agarose bound proteins were analysed by Western blotting using either the rat polyclonal anti-PRMT3 antibody (Tang et al., 1998) or the anti-DAL-1/4.1B antibody (Tran et al., 1999) detected with either mouse IgG or rabbit IgG ImmunStar Chemiluminescence kits (BioRad).
Coimmunoprecipitation analysis of other PRMT family members PRMT1, 2, 4, 5 and 6 with DAL-1/4.1B were performed as described above except that Lipofectamine 2000 was used for some transfections. Immunoprecipitates collected on Protein A agarose beads were washed with either 1 Â PBS (9 g/L NaCl, 0.144 g/L KH 2 PO 4 , 0.795 g/L NH 2 HPO 4 , pH 7.5) or 1 Â TTBS (0.1% Tween, 20 mM Tris, pH 7.5. 0.5 M NaCl). Immunoprecipitated PRMT1 was detected using a rat polyclonal anti-PRMT1 antibody (Lin et al., 1996) (1 : 5000), while PRMT 2, 4 and 6 were detected using the mouse anti-Xpress antibody (InVitrogen) (1 : 2500). PRMT5 was detected using a mouse anti-PRMT5 antibody (Upstate Biotech) (1 : 1000).
In vitro binding assays
For binding domain localization, pGEX plasmids expressing rat recombinant GST fusion proteins GST-PRMT3, GST-PRMT3DZF (PRMT3 C-terminal amino acids 184-528) and GST-ZF (PRMT3 N-terminal amino acids 1-183) described previously were used and are schematically illustrated in Figure 1 . Fusion proteins were expressed in BL-21 cells (Novagen) after induction with 0.4 mM isopropyl-b-D-thiogalactopyranoside(IPTG ). Purified GST-fusion proteins were isolated using the Bug-Bustert GST-Bindt purification kit (Novagen). Full-length [ 3 H]leucine-labeled DAL-1/4.1B and PRMT3 proteins were generated by coupled in vitro transcription and translation (TnT; Promega). Individually labeled proteins were confronted with an excess of GST-DAL-1/4.1B, GST-PRMT3, GST-14-3-3b, GST-PRMT3DZF or GST-ZF in Bug Buster binding/wash buffer (4.3 mM Na 2 HPO 4 , 1.47 mM KH 2 PO 4 , 137 mM NaCl 2 , 2.7 mM KCl, pH 7.3). Complexes were collected on GST-Bind resin (Novagen), washed several times with Bug Buster binding/wash buffer and separated on 10% SDS-PAGE gels. Gels were fixed in an isopropanol : water : acetic acid (25 : 65 : 10) solution and fluorographic signals were enhanced using Amplifyt (Amersham). Vacuum-dried gels were exposed to autoradiographic film for 1-5 days.
In vitro binding assays assessing PRMT and Protein 4.1 family interactions were also performed. Protein 4.1 family member binding to PRMT3 (Figure 4 ) was performed with NF2/merlin, ezrin, radixin, 4.1G and 4.1R80 as previously described . In vitro binding of DAL-1/4.1B to PRMT family members 1-6 ( Figure 5 ) was performed as described above except Glutathione Sepharose 4B (Pharmacia Biotech) was used to collect complexes followed by several washes in 1 Â TTBS.
In vitro methylation reactions
The preparation of GST-PRMT3 and GST-GAR and the procedure for the methylation reactions have been described previously (Tang et al., 1998; Frankel and Clarke, 2000) . GST-DAL-1/4.1B and GST-DFERM (a DAL-1/4.1B cDNA deleted for the FERM domain (Tran et al., 1999) ) were prepared as described above but purified as described in Frankel and Clarke, (2000) with more extensive washing of the glutathionebeads prior to elution. Here, 10 ml of 50 mM Na 2 HPO 4 , 137 mM NaCl 2 and 2.7 mM KCl, pH 7.5 are added to the beads and the mixture rotated for 10 min at 41C. This wash step is repeated twice more. A second wash step is then performed by rotating the beads for 10 min at 41C with 10 ml of 137 mM NaCl 2 , 2.7 mM KCl, 4.3 mM Na 2 HPO 4 , 1.4 mM KH 2 PO 4 (pH 7.4) and this was repeated twice more. Finally, the fusion protein was eluted from the beads with 30 mM glutathione, 50 mM Tris-HCl and 120 mM NaCl 2 .
For the methylation reactions, GST-PRMT3 and GST-GAR were incubated with either GST-DAL-1/4.1B or GST-DFERM in the presence of S-adenosyl-L-[methyl-
3 H]methionine ([ 3 H]AdoMet; 77 Ci/mmol from a 10.4 mM stock solution in dilute HCl/ethanol 9 : 1, pH 2.0-2.5; Amersham Biosciences) for 30-60 min at 371C. GST-GAR is a protein arginine methyltransferase substrate containing the first 148 amino acids of the human fibrillarin protein that includes 14 arginine residues within a glycine-rich region, the majority of which reside in 'RGG' consensus methylation sites (Lischwe et al., 1985) . Methylation reactions were quenched by the addition of an equal volume of 2 Â SDS-PAGE sample buffer (120 mM Tris-HCl, pH 6.8, 1.43 M 2-mercaptoethanol, 4% SDS, 24% glycerol, 0.002% bromphenol blue), heated at 1001C for 5 min, and separated on SDS-PAGE gels for 4 h. Following electrophoresis, gels were soaked in EN 3 HANCE (Perkin Elmer Life Sciences) according to the manufacturer's instructions, then dried under vacuum. Radioactivity was visualized by autoradiography at À801C with exposure times varying from 3 h to 1 week.
Methylation assays with DAL-1/4.1B-inducible. MCF-7 cell line Cl27
The MCF-7 cl27 DAL-1/4.1B-inducible cell line has been described previously (Charboneau et al., 2002) . Cells were grown to approximately 80-90% confluence with and without 2 mM DAL-1/4.1B expression-inducing muristerone DAL-1/4.1B inhibits PRMT3 methyltransferase activity V Singh et al
